Eric Anderson
Hematology & Oncology · Hood River, ORNPI 1477765493
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,715 of the $1,891 with a category attached, or 90.7%. AstraZeneca accounts for 96.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $1,665 and has fallen 99.1% since, to $15 in 2024.
Across 5 payments — averaging $378.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Ipsen Biopharmaceuticals, Inc$50
- AVEO Pharmaceuticals, Inc.$15
- Merck$11
Across 38 payments — averaging $13,207 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$365K
- AbbVie$93K
- Ipsen Bioscience Inc.$23K
- Pharmacyclics LLC, An Abbvie Company$16K
- Eli Lilly$4K
What the payments were for
- Consulting fees$1,71591%
- Speaking & faculty fees$1508%
- Education$261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 2 | $1,815 |
| Ipsen Biopharmaceuticals, Inc | 1 | $50 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,891 in reported general payments places this provider in the 65th percentile of 112 hematology & oncology providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 20 | $310,385 |
| NubeqaDarolutamide | 12 | $167,068 |
| EliquisApixaban | 61 | $55,190 |
| Abiraterone Acetate | 30 | $43,747 |
| Imatinib Mesylate | 15 | $21,109 |
| XareltoRivaroxaban | 18 | $16,629 |
| Fentanyl | 21 | $5,251 |
| Hydroxyurea | 66 | $2,006 |
| Hydromorphone Hcl | 25 | $1,789 |
| Letrozole | 68 | $1,572 |
| Tamoxifen Citrate | 27 | $1,362 |
| Anastrozole | 46 | $1,151 |
| Ondansetron Hcl | 45 | $947 |
| Oxycodone Hcl | 44 | $788 |
| Prochlorperazine Maleate | 59 | $781 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $1,815 | $310,38520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 112 hematology & oncology providers in Oregon.
Other hematology & oncology in Hood River
- Brian DrukerPortland$1.9M
- Bo WangCorvallis$251K
- Jay AndersenPortland$196K
- Richard MaziarzPortland$174K
- Tibor KovacsovicsPortland$119K
- Christopher YasenchakEugene$102K
- Elie TraerPortland$72K
- Luke FletcherEugene$44K
- Jeffrey MenashePortland$38K
- Michael HeinrichPortland$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.